Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EPS (Basic) (2016 - 2025)

Ligand Pharmaceuticals' EPS (Basic) history spans 16 years, with the latest figure at $2.4 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 239.53% year-over-year to $2.4; the TTM value through Dec 2025 reached $6.44, up 5053.85%, while the annual FY2025 figure was $6.44, 3027.27% up from the prior year.
  • EPS (Basic) for Q4 2025 was $2.4 at Ligand Pharmaceuticals, down from $5.99 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $5.99 in Q3 2025 and bottomed at -$2.88 in Q2 2024.
  • The 5-year median for EPS (Basic) is $0.2 (2023), against an average of $0.56.
  • The largest annual shift saw EPS (Basic) plummeted 2315.38% in 2024 before it skyrocketed 1635.9% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.33 in 2021, then crashed by 666.67% to -$2.53 in 2022, then surged by 145.06% to $1.14 in 2023, then tumbled by 250.88% to -$1.72 in 2024, then skyrocketed by 239.53% to $2.4 in 2025.
  • Per Business Quant, the three most recent readings for LGND's EPS (Basic) are $2.4 (Q4 2025), $5.99 (Q3 2025), and $0.26 (Q2 2025).